Sanofi-Aventis, which has been unsuccessful recently in its courtship of U.S. giant biotech Genzyme, announced another setback today. A late-stage trial of NV1FGF did not meet its primary goal of preventing a major amputation or death from any cause over 12 months.
Continue reading Another Blow for Sanofi-Aventis as a Promising Drug Fails to Deliver
Another Blow for Sanofi-Aventis as a Promising Drug Fails to Deliver originally appeared on DailyFinance on Wed, 22 Sep 2010 10:40:00.
Filed Under: Company News, Investing, Health Care, Genzyme Corporation , Sanofi Aventis, Stocks in the News